First invasive brain-computer interface medical device approved for market launch; Medical Equipment ETF (159873) benchmark index surges, rising nearly 1%, institutions: Medical equipment sector welcomes earnings improvement and valuation recovery opportunities

On March 13, the three major A-share indices fluctuated in the afternoon, with the CSI All Share Index for Medical Care Equipment and Services rising by 0.68% as of the latest report.

Among related ETFs, the Medical Equipment ETF (159873) had a trading volume of nearly 5 million yuan as of the latest report, with an over-issuance rate of 0.22%, and active trading during the session. Leading the gains among constituent stocks were China Red Medical, Yingke Medical, and Yingkang Life.

In terms of capital flow, Wind data shows that by March 12, the Medical Equipment ETF (159873) had 13 days of net capital inflow over the past 20 days, accumulating nearly 17 million yuan in “fund attraction.”

Medical Equipment ETF (159873) tracks the CSI All Share Index for Medical and Healthcare Equipment and Services. The index has a high allocation to brain-computer interface concepts, accounting for over 19%. Its constituent stocks include nearly 80% from the STAR Market and ChiNext, covering brain interface concepts such as Sanbo Brain, Xiangyu Medical, and Weisi Medical.

According to CCTV News, the first invasive brain-computer interface medical device has been approved for listing. The product includes a brain-computer interface implant, an implantable EEG electrode set, EEG signal transceivers, pneumatic gloves, a disposable surgical toolkit, EEG decoding software, medical testing software, and clinical management software. It is suitable for patients with limb paralysis caused by cervical spinal cord injury, assisting in restoring hand grasping functions through pneumatic gloves.

CITIC Construction Investment pointed out that the long-term investment opportunities in the medical device sector come from innovation, globalization, and mergers and acquisitions. The sector’s innovation and internationalization capabilities are gaining recognition, and valuations are being reassessed. By 2026, the sector is expected to see performance improvement and valuation recovery, with a focus on targets with accelerated growth, overseas expansion, and technological themes such as brain-computer interfaces and AI medical applications. Under policy optimization, high-value consumables and medical equipment segments are gradually clearing centralized procurement impacts, with ongoing progress in localization and internationalization, creating significant structural opportunities.